Globe Life (GL) Q3 2024 earnings summary

Executive summary

• Net income for Q3 2024 was $303 million ($3.44/share), up from $257 million ($2.68/share) a year ago; net operating income rose 29% year-over-year to $308 million ($3.49/share).

• Net income for the nine months ended September 30, 2024, increased 17% year-over-year to $816 million, with diluted EPS up 24% to $8.93.

• Book value per share excluding AOCI rose 13% year-over-year to $83.92.

• Life and health premium revenues grew 4% and 7% year-over-year, respectively, with strong agent count growth across key divisions.

• 5.8 million shares were repurchased for $580 million during Q3; 9.7 million shares for $910 million in the first nine months of 2024.

Financial highlights

• Life insurance premium revenue for Q3 was $819 million (+4% YoY); life underwriting margin rose 29% to $387 million, driven by a remeasurement gain from assumption unlocking.

• Health insurance premium revenue was $354 million (+7% YoY); health underwriting margin declined 10% to $87 million due to a remeasurement loss.

• Net investment income for Q3 was $285 million (+7% YoY); for the nine months ended September 30, 2024, it was $853 million, up 9% year-over-year.

• Administrative expenses ratio increased to 7.5% of premium from 6.7% year-over-year, mainly due to higher IT, legal, and employee costs.

• Excess investment income rose 33% to $126 million for the nine months, with per share up 41% to $1.38.

Outlook and guidance

• 2024 net operating EPS guidance raised to $12.20–$12.40 (midpoint $12.30); 2025 net operating EPS expected at $13.20–$13.90 (midpoint 10% growth).

• Life premium revenue to grow 4.5–5%, health 7.5–8.5% in 2025.

• Underwriting margins as a percent of premium expected at 39–42% for life and 26–28% for health in 2025.

• Management expects continued premium and sales growth, with operating ROE (excluding AOCI) in the mid-teens.

• Share repurchases are expected to remain a primary use of excess cash, subject to maintaining target capital levels.